Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

被引：0
|
作者：
Amrein, Philip C.
Attar, Eyal C.
Fathi, Amir Tahmasb
McAfee, Steven L.
Wadleigh, Martha
DeAngelo, Daniel J.
Steensma, David P.
Foster, Julia
Stone, Richard M.
Neuberg, Donna S.
Ballen, Karen K.
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA
[2] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6621
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.
    George, Tracy
    Patel, Jay L.
    Abedi, Mehrdad
    Cogle, Christopher R.
    Erba, Harry Paul
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Kiselev, Pavel
    Komrokji, Rami S.
    Louis, Chrystal Ursula
    Maciejewski, Jaroslaw P.
    Nifenecker, Melissa
    Pollyea, Daniel Aaron
    Roboz, Gail J.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Thompson, Michael A.
    Foucar, Kathryn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
    Huetter, Marie-Luise
    Fiedler, Walter
    Kuendgen, Andrea
    Krauter, Juergen
    von Lilienfeld-Toal, Marie
    Kayser, Sabine
    Rafler, Heidi
    Doehner, Hartmut
    Schlenk, Richard F.
    BLOOD, 2010, 116 (21) : 1350 - 1351
  • [33] A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Skikne, B. S.
    Ward, M. R.
    Nasser, A.
    Aukerman, L.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?
    Platzbecker, U.
    Germing, U.
    LEUKEMIA, 2013, 27 (09) : 1813 - 1819
  • [35] REDIFINING MONOSOMY 20 BY MOLECULAR CYTOGENETICS IN 1.0 MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA (MDS/AML) PATIENTS
    Bernasconi, P.
    Dambruoso, I.
    Boni, M.
    Zappatore, R.
    Cavigliano, P. M.
    Giardini, I.
    Calatroni, S.
    Rocca, B.
    Caresana, M.
    Tarantino, P.
    Lazzarino, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 273 - 273
  • [36] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [37] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [38] Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Sallman, David A.
    DeZern, Amy
    Sweet, Kendra
    Steensma, David P.
    Cluzeau, Thomas
    Sekeres, Mikkael
    Garcia-Manero, Guillermo
    Roboz, Gail
    McLemore, Amy
    McGraw, Kathy
    Puskas, John
    Zhang, Ling
    Bhagat, Chirag
    Graber, Armin
    Al Ali, Najla H.
    Padron, Eric
    Tell, Roger
    Lancet, Jeffrey E.
    Fenaux, Pierre
    List, Alan F.
    Komrokji, Rami S.
    CANCER RESEARCH, 2018, 78 (13)
  • [39] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Skikne, Barry
    Cogle, Christopher R.
    Ning, Yuhong
    MacBeth, Kyle J.
    Laille, Eric
    Ward, M. Renee
    BLOOD, 2009, 114 (22) : 53 - 53
  • [40] A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
    Garcia-Manero, G
    Faderl, S
    Giles, F
    Thomas, D
    Cortes, J
    O'Brien, S
    Davis, J
    Kantarjian, HM
    Estey, E
    HAEMATOLOGICA, 2002, 87 (08) : 804 - 807
12345